Clinical trials: COVID-19 Acute Respiratory Distress Syndrome
COVID, Corona Virus Infection
RIC as an Adjunct Therapy for Severe COVID-19 Disease: a Prospective Randomized Pilot Study
This research aims to assess the use of an experimental and non-invasive procedure, Remote Ischemic Conditioning (RIC), as an adjunct therapy in attenuating severe COVID-19 disease.
- Conditions
- COVID, Corona Virus Infection, Acute Lung Injury, Ischemia Limb
- Trial name
- NCT04659460
- Testing
- Remote Ischemic Conditioning
- Volunteers
- 30 people
- Sponsor
- Unity Health Toronto
COVID-19 Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation Complication
Quality of Life 1y and 2 y After VV-ECMO for COVID-19
This study aims to investigate the quality of life and the outcome after veno-venous extracoporeal membrane oxygenation (ECMO) support fir severe acute respiratory syndrome (ARDS) in COVID-19 patients.
- Conditions
- COVID-19 Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation Complication, Quality of Life, Death
- Trial name
- NCT05780255
- Testing
- VV-ECMO
- Where
- Belgium
- Volunteers
- 28 people
- Sponsor
- University Hospital, Ghent
COVID-19
Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19).
This is a bicentric, phase 2, randomized, open-label study to evaluate the efficacy and safety of maraviroc associated with standard treatment in hospitalized patients with pulmonary SARS-CoV-2 infection (COVID-19).
- Trial name
- MARACOVID (NCT04441385)
- Testing
- Maraviroc 300 mg, Standard care therapy
- Where
- 2 sites in Spain
- Volunteers
- 60 people
- Sponsor
- Hospital Universitario Infanta Leonor
COVID-19 Acute Respiratory Distress Syndrome
Personalized Targeted Immunomodulation in COVID-19 ARDS
Rationale: In COVID19 single-targeted immunomodulation, mostly via an IL-6 receptor blocker, was used by a one-size fits all non-targeted approach. In future pandemics the same might occur.
- Trial name
- COMODULATE (NCT06311448)
- Testing
- Single target immunomodulation, Standard of care
- Where
- Netherlands
- Volunteers
- 164 people
- Sponsor
- Erasmus Medical Center
ARDS, Human, COVID-19 Acute Respiratory Distress Syndrome
Characterization of the microVAScular Dysfunction in Covid-19 ARDS
The primary endpoint of this research is to establish that the alveolar dead space is significantly higher in patients with COVID-19 ARDS, compared to patients with non-COVID-19 ARDS.
- Trial name
- VASCOV (NCT05074758)
- Testing
- alveolar dead-space quantification, Coagulation activation and impaired fibrinolysis explorations, Endothelial activation / endothelial senescence
- Where
- France
- Volunteers
- 39 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
COVID-19
Tocilizumab Versus Baricitinib in Patients With Severe COVID-19
The aim of this study is to investigate whether baricitinib is non-inferior to tocilizumab in severe COVID-19.
- Trial name
- NCT05082714
- Testing
- Tocilizumab, Baricitinib
- Where
- Greece
- Volunteers
- 251 people
- Sponsor
- University Hospital of Patras
Acute Lung Injury, ALI
A Study of RLS-0071 in Patients With Acute Lung Injury Due to COVID-19 Pneumonia in Early Respiratory Failure
The aim of this study will test the safety, tolerability, and efficacy of RLS-0071 for approximately 28 days in comparison to a placebo control in patients with acute lung injury due to COVID-19 pneumonia in early respiratory…
- Conditions
- Acute Lung Injury, ALI, COVID-19
- Trial name
- NCT04574869
- Testing
- RLS-0071 10 mg/kg, RLS-0071 40 mg/kg
- Where
- United States
- Sponsor
- ReAlta Life Sciences, Inc.
Sarcopenia, Covid19
Sarcopenia and Related Factors in Coronavirus Disease 2019 (COVID-19) Following Intensive Care
The primary aim of this study is to evaluate the patients who had pneumonia or severe acute respiratory distress syndrome (ARDS) due to COVID-19 in terms of sarcopenia and related factors following Intensive Care Unit (ICU).
- Conditions
- Sarcopenia, Covid19, Intensive Care Unit Acquired Weakness
- Trial name
- NCT05474157
- Testing
- Standard care treatment for COVID-19 in Intensive Care Unit
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Koç University
COVID-19, Acute Respiratory Distress Syndrome
DEXamethasone EARLY Administration in Hospitalized Patients With Covid-19 Pneumonia
The aim of this study is to evaluate the efficacy of dexamethasone in hospitalized adults with COVID-19 pneumonia who do not require supplementary oxygen on admission, but have high risk of developing acute respiratory distress…
- Conditions
- COVID-19, Acute Respiratory Distress Syndrome, Pneumonia, Viral
- Trial name
- EARLYDEXCoV2 (NCT04836780)
- Testing
- Dexamethasone
- Where
- 3 sites in Spain
- Volunteers
- 126 people
- Sponsor
- Hospital Universitario Infanta Leonor
COVID-19, SARS-CoV2 Infection
Awake Prone Positioning in Moderate to Severe COVID-19
The purpose of this study is comparing vital signs between standard care and prone position groups. Standard care will consist of routine clinical care, including any advice to lie in prone position as routinely recommended by…
- Conditions
- COVID-19, SARS-CoV2 Infection, COVID-19 Acute Respiratory Distress Syndrome, Acute Hypoxemic Respiratory Failure
- Trial name
- NCT05083130
- Testing
- a wake prone positioning
- Where
- Vietnam
- Volunteers
- 93 people
- Sponsor
- Oxford University Clinical Research Unit, Vietnam
COVID-19 Acute Respiratory Distress Syndrome, Cytokine Release Syndrome
Tazemetostat for the Treatment of Moderate to Severe COVID-19 Infection
The purpose of this study is to assess the safety and efficacy of repurposing tazemetostat for the treatment of Acute Respiratory Distress Syndrome (ARDS) or Systemic Cytokine Release Syndrome (SCRS) in COVID-19 patients.
- Trial name
- IST (NCT05018975)
- Testing
- Tazemetostat
- Volunteers
- healthy volunteers welcome
- Sponsor
- Loma Linda University
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome
Study of Cord Blood Derived Mesenchymal Stem Cells for Treatment of Moderate, Severe or Critical Pneumonia
This is a phase I trial followed by a phase II randomized trial. The purpose of phase I study is the feasibility of treating patients with acute respiratory distress syndrome (ARDS) related to COVID-19 infection (COVID-19) with…
- Conditions
- COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
- Trial name
- NCT04565665
- Testing
- Best Practice, Mesenchymal Stem Cell
- Where
- United States
- Volunteers
- 65 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure
Effects of mTOR Inhibition With Sirolimus (RAPA) in Patients With COVID-19 to Moderate the Progression of ARDS
This study assesses the clinical effectiveness of mammalian target of rapamycin (mTOR) inhibition with rapamycin in minimizing or decreasing the severity of acute lung injury/acute respiratory distress syndrome (ALI/ARDS) in…
- Conditions
- Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS), Respiratory Failure, Sars-CoV2
- Trial name
- RAPA-CARDS (NCT04482712)
- Testing
- Rapamycin
- Where
- 2 sites in United States
- Sponsor
- The University of Texas Health Science Center at San Antonio
Mechanical Ventilation Complication, Hypoxemia
Trial of Venovenous ECMO to De-Sedate, Extubate and Mobilise in Hypoxic Respiratory Failure
To determine whether a strategy of adding venovenous ECMO to mechanical ventilation, as compared to mechanical ventilation alone, increases the number of intensive care free days at day 60, in patients with moderate to severe…
- Conditions
- Mechanical Ventilation Complication, Hypoxemia, Acute Respiratory Distress Syndrome Due to COVID-19, COVID-19 Respiratory Infection
- Trial name
- REDEEM (NCT05562505)
- Testing
- Venovenous ECMO
- Where
- 7 sites in Australia, Germany
- Volunteers
- 140 people
- Sponsor
- Australian and New Zealand Intensive Care Research Centre
Acute Lung Injury (ALI) Associated With COVID-19, Lung Inflammation Associated With COVID-19
TD-0903 for ALI Associated With COVID-19
This Phase 2 study will evaluate the efficacy, safety, pharmacodynamics and pharmacokinetics of inhaled TD-0903 compared with a matching placebo in combination with standard of care (SOC) in hospitalized patients with confirmed…
- Trial name
- NCT04402866
- Testing
- TD-0903
- Where
- 24 sites in United States, Brazil and 5 more
- Volunteers
- 235 people
- Sponsor
- Theravance Biopharma
Severe Acute Respiratory Syndrome Coronavirus 2
Vagus Nerve Stimulation ARDS Prevention Trial for COVID-19 Hospitalized Patients
This trial is designed to determine if the inflammation modulating effect of vagus nerve stimulation can improve pulmonary function and limit progression to ARDS in hospitalized COVID-19 hospitalized patients.
- Trial name
- NCT04379037
- Testing
- Transcutaneous Auricular Vagus Nerve Stimulation
- Where
- Argentina
- Volunteers
- 50 people
- Sponsor
- Nemechek Technologies
Covid19, Sars-CoV-2 Infection
Management of Cytokine Storms in Severe COVID-19 Patients With Autologous Activated Platelet-rich Plasma Therapy
The positive cases of coronavirus disease-2019 (COVID-19) in Indonesia has been increasing rapidly since the first case found in March 2020 to date.
- Conditions
- Covid19, Sars-CoV-2 Infection, ARDS, Human, Severe covid19
- Trial name
- NCT04715360
- Testing
- autologous activated platelet-rich plasma, Avigan
- Where
- Indonesia
- Volunteers
- 30 people
- Sponsor
- Hayandra Peduli Foundation
ARDS Due to COVID-19
Surfactant-BL in Adult Acute Respiratory Distress Syndrome Due to COVID-19
The purpose of this study is to prove the efficacy and safety Surfactant-BL, administered by inhalation in adult hospitalized patients with ARDS due to COVID-19.
- Trial name
- NCT04568018
- Testing
- Surfactant
- Where
- Russia
- Volunteers
- 120 people
- Sponsor
- Biosurf LLC.
COVID-19 Acute Respiratory Distress Syndrome, Cognitive Decline
Cognitive Functions After COVID-19
This study was aimed to evaluate the post-infection cognitive functions of adult individuals with COVID-19. 50 individuals with COVID-19 and 50 healthy control groups were included in the study.
- Trial name
- NCT04978246
- Testing
- Neuropsychometric Test
- Where
- Turkey (Türkiye)
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Medipol University
COVID-19, ARDS, Human
WeanINg From Mechanical Ventilation for ARDS CovId-19 Patients Guided by Combined Thoracic UltraSound.
The most feared complication of COVID-19 infection is the occurrence of an acute respiratory distress syndrome (ARDS) that requires ICU admission and prolonged mechanical ventilation in more than 2% of the affected patients.
- Conditions
- COVID-19, ARDS, Human, Mechanical Ventilation
- Trial name
- INVICTUS (NCT04372680)
- Testing
- CTUS examination
- Where
- 2 sites in France
- Volunteers
- 89 people
- Sponsor
- University Hospital, Toulouse